MD1105

MD1105 is a pre-clinical stage drug candidate developed by MedDay Pharmaceuticals as a disease-modifying therapy for Alzheimer's disease. While the specific chemical structure and mechanism of action have not been publicly disclosed, the program leverages MedDay's expertise in targeting the metabolism of the nervous system, a strategy derived from the study of rare inborn errors of metabolism. The drug is intended to address the underlying metabolic dysfunctions associated with neurodegenerative progression. As of the available information, the asset was in the pre-clinical phase with the developer anticipating clinical entry.